P Elleringmann
YOU?
Author Swipe
View article: P08.23.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA
P08.23.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GB) is the most frequent primary brain tumor with a dismal prognosis despite multimodal treatment regimens. Effector cell therapies with T cells or natural killer cells (NK) carrying tumor-specific chimeric antigen…
View article: P08.08.B CAR-NK CELL THERAPY COMBINED WITH CHECKPOINT INHIBITION INDUCES A DISTANT ANTI-TUMOR RESPONSE IN AN IMMUNOCOMPETENT GLIOBLASTOMA MOUSE MODEL
P08.08.B CAR-NK CELL THERAPY COMBINED WITH CHECKPOINT INHIBITION INDUCES A DISTANT ANTI-TUMOR RESPONSE IN AN IMMUNOCOMPETENT GLIOBLASTOMA MOUSE MODEL Open
BACKGROUND Glioblastoma (GB) is the most common and aggressive primary brain tumor with limited efficacy of standard therapy. The GB tumor microenvironment (TME) is characterized by pronounced immunosuppression, with PD-L1 expression on gl…
View article: Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsets
Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsets Open
Precise in vivo gene delivery to specific cell types remains a significant challenge in gene therapy, particularly for cancer immunotherapy applications. Here, we rationally engineered AAV9 to become a modular, receptor-targeted vector for…
View article: CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma Open
View article: P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA
P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GB) is the most frequent primary brain tumor and despite intensive treatment regimens including surgery, radiotherapy, and chemotherapy, it is still characterized by a dismal prognosis. Immunotherapies such as T ce…